Bristol-Myers Squibb (BMY) Q4 FY2025 earnings: revenue $12.5 billion, up 1.3% on the year
Bristol-Myers Squibb Co. (BMY) reported revenue of $12.5 billion for Q4 FY2025, the quarter ended 31 December 2025, up 1.3% on the same quarter a year earlier. Net income was $1.1 billion, up 1409.7% on the year, and diluted earnings per share $0.53. The figures are the company's own, from the 10-K it filed with the SEC on 11 February 2026.
Revenue
$12.5 billion
+1.3% on the year · +2.3% on the quarter
Q1 FY2024Q4 FY2025
Operating margin
11.8%
1.4% a year earlier
Q1 FY2024Q4 FY2025
Net income
$1.1 billion
+1,409.7% on the year · -50.6% on the quarter
Q1 FY2024Q4 FY2025
Diluted EPS
$0.53
+1,225.0% on the year · -50.9% on the quarter
Q1 FY2024Q4 FY2025
this quarterthe same quarter a year earlierHover a bar for its figure.
What management said
Guidance figures: 9 new.
Fourth-quarter revenue rose 1%: Total revenues were $12.5 billion, up 1% and flat excluding foreign exchange. Growth Portfolio revenues rose 16% to $7.4 billion, while Legacy Portfolio revenues fell 15%.
Full-year non-GAAP EPS was $6.15: Full-year non-GAAP EPS was $6.15 and GAAP EPS was $3.46. The October 2025 release had set a non-GAAP EPS range of $6.40 to $6.60 for the year.
Legacy Portfolio down 15% in quarter: Legacy Portfolio revenues were $5.1 billion in the fourth quarter, down 15% or 16% excluding foreign exchange.
$ million except per share. Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q4 FY2025
Q3 FY2025
Q4 FY2024
On the quarter
On the year
Last 8 quarters
Operating cash flow
1,974
6,311
4,439
-68.7%
-55.5%
Capital expenditure
370
320
378
+15.6%
-2.1%
Free cash flow
1,604
5,991
4,061
-73.2%
-60.5%
Free cash flow margin
12.8%
49.0%
32.9%
Cash from investing
-1,458
-1,702
-196
Cash from financing
-6,029
-1,490
-1,642
Depreciation and amortisation
944
1,026
1,941
-8.0%
-51.4%
Share-based compensation
132
139
120
-5.0%
+10.0%
Buybacks
n/a
n/a
0.0
Dividends paid
1,262
1,263
1,218
-0.1%
+3.6%
Dividend per share
n/a
$0.62
n/a
Diluted shares, weighted
2,041m
2,039m
2,037m
+0.1%
+0.2%
Shares outstanding at period end
2,036m
2,036m
2,029m
+0.0%
+0.4%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q4 FY2025
Q3 FY2025
Q4 FY2024
On the quarter
On the year
Last 8 quarters
Shareholders' equity
18,473
18,552
16,335
-0.4%
+13.1%
Non-controlling interest
33.0
48.0
53.0
-31.2%
-37.7%
Short-term borrowings
n/a
n/a
2,046
Debt
45,111
48,978
49,431
-7.9%
-8.7%
Operating lease liabilities
1,826
1,849
1,370
-1.2%
+33.3%
Other liabilities
24,595
27,462
23,368
-10.4%
+5.3%
Total liabilities and equity
90,038
96,889
92,603
-7.1%
-2.8%
Fixed assets
7,543
7,349
7,136
+2.6%
+5.7%
Goodwill
21,754
21,745
21,719
+0.0%
+0.2%
Intangible assets
19,103
20,465
23,307
-6.7%
-18.0%
Investments
860
1,182
833
-27.2%
+3.2%
Cash and equivalents
10,209
15,726
10,346
-35.1%
-1.3%
Receivables
9,592
9,624
9,012
-0.3%
+6.4%
Inventory
2,690
2,758
2,557
-2.5%
+5.2%
Other assets
18,287
18,040
17,693
+1.4%
+3.4%
Total assets
90,038
96,889
92,603
-7.1%
-2.8%
Questions
What was Bristol-Myers Squibb's revenue in Q4 FY2025?
Bristol-Myers Squibb (BMY) reported revenue of $12.5 billion for Q4 FY2025, the quarter ended 31 December 2025, up 1.3% on the same quarter a year earlier.
How much did Bristol-Myers Squibb earn in Q4 FY2025?
Net income for Q4 FY2025 was $1.1 billion, up 1409.7% on the year, and diluted earnings per share $0.53.
When did Bristol-Myers Squibb report Q4 FY2025 results?
Bristol-Myers Squibb filed its 10-K for the year that ended with the quarter on 11 February 2026; the fourth quarter is the year less the first three.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-K for the period ended 31 December 2025, filed 11 February 2026: the filing.